메뉴 건너뛰기




Volumn 17, Issue 2, 1999, Pages 658-667

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; TOPOTECAN; VINCRISTINE;

EID: 0033044111     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.658     Document Type: Article
Times cited : (856)

References (38)
  • 1
    • 0026500785 scopus 로고
    • Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: Phase III trial of Southeastern Cancer Study Group
    • Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: Phase III trial of Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
    • (1992) J Clin Oncol , vol.10 , pp. 282-291
    • Roth, B.J.1    Johnson, D.H.2    Einhorn, L.H.3
  • 2
    • 0025898914 scopus 로고
    • Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
    • Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991
    • (1991) J Natl Cancer Inst , vol.83 , pp. 855-861
    • Fukuoka, M.1    Furuse, K.2    Saijo, N.3
  • 3
    • 0025204765 scopus 로고
    • A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small-cell lung cancer
    • Sculier JP, Klastersky J, Libert P, et al: A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small-cell lung cancer. Lung Cancer 6:110-118, 1990
    • (1990) Lung Cancer , vol.6 , pp. 110-118
    • Sculier, J.P.1    Klastersky, J.2    Libert, P.3
  • 4
    • 0023201152 scopus 로고
    • Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin-resistant small-cell lung cancer
    • Shepherd FA, Evans WK, MacCormick R, et al: Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin-resistant small-cell lung cancer. Cancer Treat Rep 71:941-944, 1987
    • (1987) Cancer Treat Rep , vol.71 , pp. 941-944
    • Shepherd, F.A.1    Evans, W.K.2    MacCormick, R.3
  • 6
    • 0012115877 scopus 로고
    • Neoplasms of the lung
    • Isselbacher KJ, Braunwald E, Wilson JD, et al (eds): New York, McGraw-Hill
    • Minna JD: Neoplasms of the lung, in Isselbacher KJ, Braunwald E, Wilson JD, et al (eds): Harrison's Principles of Internal Medicine. New York, McGraw-Hill, 1994, pp 1221-1229
    • (1994) Harrison's Principles of Internal Medicine , pp. 1221-1229
    • Minna, J.D.1
  • 11
    • 0030913459 scopus 로고    scopus 로고
    • Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
    • Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090-2096, 1997
    • (1997) J Clin Oncol , vol.15 , pp. 2090-2096
    • Ardizzoni, A.1    Hansen, H.2    Dombernowsky, P.3
  • 12
    • 0002429272 scopus 로고    scopus 로고
    • Evaluation of topotecan (Hycamtin) in relapsed small-cell lung cancer (SCLC): A multicenter phase II study
    • abstr 126
    • Depierre A, von Pawel J, Hans K, et al: Evaluation of topotecan (Hycamtin) in relapsed small-cell lung cancer (SCLC): A multicenter Phase II study. Lung Cancer 18:35, 1997 (abstr 126)
    • (1997) Lung Cancer , vol.18 , pp. 35
    • Depierre, A.1    Von Pawel, J.2    Hans, K.3
  • 13
    • 0000580721 scopus 로고    scopus 로고
    • Topotecan (T) as second-line therapy in patients (pts) with small cell lung cancer (SCLC): A phase II study
    • abstr 513
    • Eckardt J, Gralla R, Palmer MC, et al: Topotecan (T) as second-line therapy in patients (pts) with small cell lung cancer (SCLC): A Phase II study. Ann Oncol 7:107, 1996 (abstr 513)
    • (1996) Ann Oncol , vol.7 , pp. 107
    • Eckardt, J.1    Gralla, R.2    Palmer, M.C.3
  • 14
    • 0000313636 scopus 로고    scopus 로고
    • Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)
    • abstr 1624
    • Eckardt J, Depierre A, Ardizzoni A, et al: Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC). Proc Am Soc Clin Oncol, 16:452a, 1997 (abstr 1624)
    • (1997) Proc Am Soc Clin Oncol , vol.16
    • Eckardt, J.1    Depierre, A.2    Ardizzoni, A.3
  • 17
    • 0026608875 scopus 로고
    • Management of small-cell lung cancer
    • Hansen HH: Management of small-cell lung cancer. Lancet 339:846-849, 1992
    • (1992) Lancet , vol.339 , pp. 846-849
    • Hansen, H.H.1
  • 18
    • 0027162262 scopus 로고
    • Predictors of survival following relapse or progression of small cell lung cancer
    • Albain KS, Crowley JJ, Hutchins L, et al: Predictors of survival following relapse or progression of small cell lung cancer. Cancer 72:1184-1191, 1993
    • (1993) Cancer , vol.72 , pp. 1184-1191
    • Albain, K.S.1    Crowley, J.J.2    Hutchins, L.3
  • 19
    • 0029758947 scopus 로고    scopus 로고
    • Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase poison topotecan
    • Perez-Soler R, Glisson BS, Lee JS, et al: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase poison topotecan. J Clin Oncol 14:2785-2790, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 2785-2790
    • Perez-Soler, R.1    Glisson, B.S.2    Lee, J.S.3
  • 20
    • 0025130651 scopus 로고
    • Prolonged administration of oral etoposide in patients with relapsed small-cell lung cancer: A phase II trial
    • Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed small-cell lung cancer: A phase II trial. J Clin Oncol 8:1613-1617, 1990
    • (1990) J Clin Oncol , vol.8 , pp. 1613-1617
    • Johnson, D.H.1    Greco, F.A.2    Strupp, J.3
  • 21
    • 0030608237 scopus 로고    scopus 로고
    • Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomized trial. Medical Research Council Lung Cancer Working Party
    • Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomized trial. Medical Research Council Lung Cancer Working Party. Lancet 348:563-566, 1996
    • (1996) Lancet , vol.348 , pp. 563-566
  • 22
    • 0030946011 scopus 로고    scopus 로고
    • Five day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy
    • Souhami RL, Spiro SG, Rudd RM, et al: Five day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89:577-580, 1997
    • (1997) J Natl Cancer Inst , vol.89 , pp. 577-580
    • Souhami, R.L.1    Spiro, S.G.2    Rudd, R.M.3
  • 23
    • 0029071979 scopus 로고
    • Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study
    • Ettinger DS, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995
    • (1995) J Clin Oncol , vol.13 , pp. 1430-1435
    • Ettinger, D.S.1    Finkelstein, D.M.2    Sarma, R.P.3
  • 24
    • 0001098464 scopus 로고
    • A phase II trial of Taxol and G-CSF in previously untreated SCLC
    • abstr 1076
    • Kirschling RJ, Jung JH, Jett JR: A phase II trial of Taxol and G-CSF in previously untreated SCLC. Proc Am Soc Clin Oncol 13:326, 1994 (abstr 1076)
    • (1994) Proc Am Soc Clin Oncol , vol.13 , pp. 326
    • Kirschling, R.J.1    Jung, J.H.2    Jett, J.R.3
  • 25
    • 0029608619 scopus 로고    scopus 로고
    • Phase II trial of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer
    • Latreille J, Cormier Y, Martins H, et al: Phase II trial of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 13:343-345, 1996
    • (1996) Invest New Drugs , vol.13 , pp. 343-345
    • Latreille, J.1    Cormier, Y.2    Martins, H.3
  • 26
    • 0344367790 scopus 로고
    • Taxotere is active in small cell lung cancer (SCLC). A phase II trial of the EORTC Early Clinical Trials Group (ECTG)
    • abstr 849
    • Smyth JF, Bowman A, Smith I, et al: Taxotere is active in small cell lung cancer (SCLC). A phase II trial of the EORTC Early Clinical Trials Group (ECTG). Eur J Cancer 29A:154, 1993 (suppl 6, abstr 849)
    • (1993) Eur J Cancer , vol.29 A , Issue.6 SUPPL. , pp. 154
    • Smyth, J.F.1    Bowman, A.2    Smith, I.3
  • 27
    • 0028071210 scopus 로고
    • Activity of docetaxel (Taxotere) in small cell lung cancer
    • Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 30A:1058-1060, 1994
    • (1994) Eur J Cancer , vol.30 A , pp. 1058-1060
    • Smyth, J.F.1    Smith, I.E.2    Sessa, C.3
  • 28
    • 0028297564 scopus 로고
    • Gemcitabine is an active new agent in previously untreated extensive small-cell lung cancer (SCLC): A study of the National Cancer Institute of Canada Clinical Trials Group
    • Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small-cell lung cancer (SCLC): A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5:283-285, 1994
    • (1994) Ann Oncol , vol.5 , pp. 283-285
    • Cormier, Y.1    Eisenhauer, E.2    Muldal, A.3
  • 29
    • 13344270908 scopus 로고    scopus 로고
    • Phase II study of vinorelbine in heavily previously treated small cell lung cancer
    • Furuse K, Kubota K, Kawahara M, et al: Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 53:169-172, 1996
    • (1996) Oncology , vol.53 , pp. 169-172
    • Furuse, K.1    Kubota, K.2    Kawahara, M.3
  • 30
    • 0027248286 scopus 로고
    • Phase II study of Vinorelbine (Navelbine) in previously treated small cell lung cancer patients
    • Jassem J, Karnicka-Mlodkowska H, Van Pottelsberghe C, et al: Phase II study of Vinorelbine (Navelbine) in previously treated small cell lung cancer patients. Eur J Cancer 29A:1720-1722, 1993
    • (1993) Eur J Cancer , vol.29 A , pp. 1720-1722
    • Jassem, J.1    Karnicka-Mlodkowska, H.2    Van Pottelsberghe, C.3
  • 31
    • 0029074323 scopus 로고
    • Pilot study of irinotecan in refractory small cell lung cancer
    • Fujita A, Takabatake H, Tagaki S, et al: Pilot study of irinotecan in refractory small cell lung cancer. Gan To Kagaku Ryoho 22:889-893, 1995
    • (1995) Gan To Kagaku Ryoho , vol.22 , pp. 889-893
    • Fujita, A.1    Takabatake, H.2    Tagaki, S.3
  • 32
    • 0026680292 scopus 로고
    • CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
    • Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
    • (1992) J Clin Oncol , vol.10 , pp. 1225-1229
    • Masuda, N.1    Fukuoka, M.2    Kusunoki, Y.3
  • 33
    • 0344799567 scopus 로고
    • CPT-11 (irinotecan) in pretreated small cell lung cancer (SCLC): A phase II study in patients progressing after a first response (preliminary results)
    • Pujol JL, Le Chevalier T, Douillard JY, et al: CPT-11 (irinotecan) in pretreated small cell lung cancer (SCLC): A phase II study in patients progressing after a first response (preliminary results). Eur J Cancer 31:821, 1995 (suppl 5)
    • (1995) Eur J Cancer , vol.31 , Issue.5 SUPPL. , pp. 821
    • Pujol, J.L.1    Le Chevalier, T.2    Douillard, J.Y.3
  • 34
    • 0029790139 scopus 로고    scopus 로고
    • Phase II study of topotecan in patients with extensive stage small-cell carcinoma of the lung: An Eastern cooperative oncology group trial
    • Schiller JH, Kim KM, Hutson P, et al: Phase II study of topotecan in patients with extensive stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 14:2345-2352, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 2345-2352
    • Schiller, J.H.1    Kim, K.M.2    Hutson, P.3
  • 35
    • 0029993118 scopus 로고    scopus 로고
    • Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel
    • letter
    • Miller AA, Lilenbaum RC, Lynch TJ, et al: Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol 14:1964-1965, 1996 (letter)
    • (1996) J Clin Oncol , vol.14 , pp. 1964-1965
    • Miller, A.A.1    Lilenbaum, R.C.2    Lynch, T.J.3
  • 36
    • 0030665426 scopus 로고    scopus 로고
    • Clinical status and optimal use of topotecan
    • Takimoto CH, Arbuck SG: Clinical status and optimal use of topotecan. Oncology 11:1635-1646, 1997
    • (1997) Oncology , vol.11 , pp. 1635-1646
    • Takimoto, C.H.1    Arbuck, S.G.2
  • 37
    • 0002963913 scopus 로고    scopus 로고
    • Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy
    • abstr 38
    • Jett JR, Day R, Levitt M, et al: Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy. Lung Cancer 18:13, 1997 (suppl 1, abstr 38)
    • (1997) Lung Cancer , vol.18 , Issue.1 SUPPL. , pp. 13
    • Jett, J.R.1    Day, R.2    Levitt, M.3
  • 38
    • 0002091930 scopus 로고    scopus 로고
    • Activity of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer and pharmacodynamics of topo-1 depletion: A NYGOG study
    • abstr 326
    • Hochster H, Speyer J, Wadler S, et al: Activity of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer and pharmacodynamics of topo-1 depletion: A NYGOG study. Ann Oncol 7:69, 1996 (abstr 326)
    • (1996) Ann Oncol , vol.7 , pp. 69
    • Hochster, H.1    Speyer, J.2    Wadler, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.